Forty-two PD patients were assigned to receive either a combination of weekly intravenous and daily oral NAC or standard care, and exhibited a significant increase in DAT binding in the caudate and putamen regions, which was associated with substantial improvements in PD symptoms. The gene discussed is SLC6A3; the disease is Parkinson disease.